Christopher Hui: The Hong Kong Stock Exchange has taken into account the needs of different investors when implementing the optimized mechanism for IPO pricing and allocation.

Xu Zhengyu mentioned that the Hong Kong Securities and Futures Commission and the Hong Kong Stock Exchange will continue to closely review the quality of sponsor work and listing applications, and take appropriate regulatory actions when necessary to uphold Hong Kong's reputation as a leading international fundraising hub.

Zhitong FinanceMay 13 13:51

IPO News | Bangshun Pharmaceutical Plans HKEX IPO; CSRC Requests Supplementary Explanation on Pricing Basis and Rationale for Previous Capital Increases and Equity Transfers

The CSRC has requested that Bangshun Pharmaceutical provide additional explanations regarding the pricing and valuation basis of all previous capital increases and equity transfers. The company must clarify whether there have been any abnormal share subscription prices, any instances of interest conveyance, whether contributions have been fully paid, and whether there are situations such as non-fulfillment of contribution obligations, withdrawal of capital, or flaws in the method of contribution.

Zhitong FinanceApr 24 20:00

At a Glance: March's Hottest IPOs - Shangmi Technology Approved! Four New Stocks, Including ZhaoWei Electromechanical and EastControl, Undergoing Enthusiastic Subscription.

Hello, fellow investors! The New Stock Observer is here to provide updates on the popular HK IPOs in March and throughout 2026. Fellow investors, check it out now!

Futu NewsFeb 28 09:55

IPO News | Bangshun Pharmaceutical Submits Listing Application to HKEX, Focusing on Oncology and Autoimmune Disease Fields

Hangzhou Bangshun Pharmaceutical Co., Ltd. has submitted its listing application to the Main Board of the Hong Kong Stock Exchange, with CITIC Securities International acting as its exclusive sponsor.

Zhitong FinanceJan 22 19:21